[HTML][HTML] The role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome

K Bednarz, K Kowalczyk, M Cwynar, D Czapla… - International journal of …, 2022 - mdpi.com
Insulin resistance is documented in clamp studies in 75% of women with polycystic ovary
syndrome (PCOS). Although it is not included in the diagnostic criteria of PCOS, there is a …

Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis

N Naderpoor, S Shorakae, B de Courten… - Human reproduction …, 2015 - academic.oup.com
BACKGROUND Polycystic ovary syndrome (PCOS) is a common endocrine disorder with
diverse reproductive and metabolic features. It is underpinned by insulin resistance that is …

American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with …

WT Garvey, JI Mechanick, EM Brett, AJ Garber… - Endocrine Practice, 2016 - Elsevier
Objective Development of these guidelines is mandated by the American Association of
Clinical Endocrinologists (AACE) Board of Directors and the American College of …

[HTML][HTML] Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized …

KE Elkind-Hirsch, N Chappell, D Shaler, J Storment… - Fertility and sterility, 2022 - Elsevier
Objective To study the efficacy and safety of the GLP-1 analog liraglutide 3 mg (LIRA 3 mg)
vs. placebo (PL) for reduction of body weight (BW) and hyperandrogenism in women with …

The current and potential therapeutic use of metformin—the good old drug

J Drzewoski, M Hanefeld - Pharmaceuticals, 2021 - mdpi.com
Metformin, one of the oldest oral antidiabetic agents and still recommended by almost all
current guidelines as the first-line treatment for type 2 diabetes mellitus (T2DM), has become …

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility

LC Morley, T Tang, E Yasmin… - Cochrane Database …, 2017 - cochranelibrary.com
Background Polycystic ovary syndrome (PCOS) is characterised by infrequent or absent
ovulation, and high levels of androgens and insulin (hyperinsulinaemia). Hyperinsulinaemia …

Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial

S Frøssing, M Nylander, E Chabanova… - Diabetes, Obesity …, 2018 - Wiley Online Library
Women with polycystic ovary syndrome (PCOS) were treated with the GLP‐1 receptor
agonist liraglutide to investigate the effect on liver fat content, visceral adipose tissue (VAT) …

Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome

M Siamashvili, SN Davis - Expert review of clinical pharmacology, 2021 - Taylor & Francis
ABSTRACT Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) offer a
unique opportunity to simultaneously address various comorbid associated conditions and …

Effects of lifestyle modification in polycystic ovary syndrome compared to metformin only or metformin addition: A systematic review and meta-analysis

CH Kim, SJ Chon, SH Lee - Scientific reports, 2020 - nature.com
Polycystic ovary syndrome (PCOS) is a common disease that has an effect on approximately
10% of women of childbearing age. Although there is evidence regarding the role of lifestyle …

The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective

M Jensterle, A Janez, E Fliers… - Human reproduction …, 2019 - academic.oup.com
Abstract BACKGROUND Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs)
have become firmly established in the treatment of type 2 diabetes and obesity, disorders …